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Abstract
Purpose—Published literature on receipt of preventive healthcare services among Asian 
American and Pacific Islander (API) cancer survivors is scarce. We describe patterns in receipt of 
preventive services among API long-term colorectal cancer (CRC) survivors.
Methods—Surveillance, Epidemiology, and End Results registry–Medicare data were used to 
identify 9,737 API and white patients who were diagnosed with CRC during 1996–2000 and who 
survived 5 or more years beyond their diagnoses. We examined receipt of vaccines, 
mammography (females), bone densitometry (females), and cholesterol screening among the 
survivors and how the physician specialties they visited for follow-up care correlated to services 
received.
Results—APIs were less likely than whites to receive mammography (52.0 vs. 69.3 %, 
respectively; P <0.0001) but more likely to receive influenza vaccine, cholesterol screening, and 
bone densitometry. These findings remained significant in our multivariable model, except for 
receipt of bone densitometry. APIs visited PCPs only and both PCPs and oncologists more 
frequently than whites (P <0.0001). Women who visited both PCPs and oncologists compared 
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with PCPs only were more likely to receive mammography (odds ratio=1.40; 95 % confidence 
interval, 1.05–1.86).
Conclusions—Visits to both PCPs and oncologists were associated with increased use of 
mammography. Although API survivors visited these specialties more frequently than white 
survivors, API women may need culturally appropriate outreach to increase their use of this test.
Implications for Cancer Survivors—Long-term cancer survivors need to be aware of 
recommended preventive healthcare services, as well as who will manage their primary care and 
cancer surveillance follow-up.
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Introduction
In 2009, colorectal cancer (CRC) was the second leading cause of cancer deaths among 
cancers that affect both men and women in the USA [1]. Given the advances in diagnosing 
CRC earlier [2], the survival rate for this disease has increased over time [3] and the number 
of cancer survivors is expected to increase [4]. Recent studies have highlighted gaps at the 
interface between primary care and specialist care during the transition to survivorship, as 
well as the importance of survivorship care plans that include promoting a healthy lifestyle 
and monitoring for cancer recurrence [5, 6]. As most cancer survivors are 50 years or older 
[7], the healthy behaviors that are promoted may include recommended preventive services 
for this age group (e.g., influenza and pneumococcal vaccination, screening for breast 
cancer, CRC, lipid disorders, and osteoporosis) [8].
Collectively, Asians and Pacific Islanders (APIs) have lower CRC rates than white, black, 
and Hispanic populations [1]; however, their exponential growth in the last 10 years [9] may 
affect their future cancer burden. Although APIs also have the lowest CRC death rates [1] 
and the highest CRC survival rates [10], CRC deaths vary when data for this population are 
disaggregated [11]. Disparities in CRC screening and other chronic disease risk factors and 
behaviors have been reported among Asian subgroups [12–14], which may contribute to 
differences in outcomes among those who are diagnosed with cancer. Little is known about 
receipt of preventive healthcare services among API cancer survivors, including whether 
disparities exist by subgroup. Previous studies that explored receipt of cancer and 
noncancer-related preventive services among cancer survivors reported that the services 
received varied over time and by the type of physician visited [15–18]. Studies that assessed 
the effect of race on these outcomes reported that whites were more likely to receive 
services than African Americans or “other” populations [15–17]. APIs were grouped in the 
latter category; therefore, data were not reported separately for them. Thus, we examine 
physician visits and receipt of preventive care among API and white long-term CRC 
survivors to describe patterns in the services they receive and how they relate to physician 
specialty. We also aim to identify any differences in the receipt of preventive care among 
API subgroups.
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Surveillance, Epidemiology, and End Results (SEER) registry data files from calendar year 
2008 and Medicare claims files (i.e., hospital, outpatient, hospice, and physician claims) for 
1996–2006 were linked and used to identify long-term CRC survivors. Detailed 
methodology has been described elsewhere [19].
To be eligible for this study, CRC survivors must have been diagnosed during 1996–2000 at 
age 60 years or older, identified as non-Hispanic API or non-Hispanic white (hereafter 
referred to as API and white) on the basis of SEER race/ethnicity, living in 16 SEER areas at 
the times of their diagnoses, and continuously enrolled in Medicare parts A and B (with no 
HMO enrollment) during 2001–2006. They also must have survived for 5 years or more 
beyond their CRC diagnoses and had no recurrences or diagnoses of another incident cancer.
We used the SEER race variable linked to Indian Health Service administration data, as well 
as the North American Association of Central Cancer Registries (NAACCR) Hispanic 
Identification Algorithm variable, to reduce misclassification of study participants [20, 21]. 
To further classify API according to ancestry or ethnic background, we used the NAACCR 
Asian Pacific Islander Identification Algorithm variable, which uses birthplace and name to 
classify API patients as Chinese, Japanese, and other API descent [22].
We identified 29,484 API and white long-term CRC survivors who lived in 16 SEER areas 
at the times of their diagnoses, were diagnosed with CRC between 1996 and 2000, survived 
for at least 5 years after their diagnoses, and were diagnosed at age 60 or above. The final 
data set for analysis was created after excluding survivors who were not continuously 
enrolled in Medicare parts A and B with no HMO enrollment (n =15,839), had another 
incident non-CRC that occurred after a CRC diagnosis in the 1996–2000 time period (n 
=1,079), and had a nonmalignant CRC diagnosis based on behavior recode (n =2,384). 
These exclusions were not mutually exclusive, and left 12,042 CRC survivors in the 
analysis. To limit the analysis to CRC survivors without a terminal illness or recurrence, we 
also excluded (1) survivors with hospice claims during the 2001– 2006 time period (n 
=225); (2) survivors who had at least one chemotherapy claim based on hospital, outpatient, 
or physician claims, with the last claim date occurring 12 months after the therapy start date 
based on SEER data (n =1,305); or (3) survivors with at least one radiation claim from either 
hospital, outpatient, or physician claims with the last claim date occurring 12 months after 
the SEER therapy start date (n =415). These exclusions were not mutually exclusive because 
some survivors had claims for hospice, chemotherapy, and radiation. In addition, one 
survivor was excluded because of a mismatch between the SEER age group category and the 
Medicare date of birth variable. An additional 261 survivors were excluded for having 
American Joint Committee on Cancer (AJCC) unknown stage, which left 9,737 survivors in 
the analysis.
Preventive medical services and type of physician administering care were analyzed from 
the beginning of the 5-year anniversary date of diagnosis through the end of the follow-up 
period, 31 December 2006. We used ICD-9 or CPT codes to assess the following preventive 
medical services received anytime during the follow-up period: influenza vaccine or 
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pneumococcal vaccine; cholesterol screening; mammography for women aged younger than 
75 years at their 5-year anniversary date of diagnosis; and bone density screening among 
women. The types of physicians visited were identified by the specialty listed on physician 
claims for Evaluation and Management visits (CPT codes: 99201–99205 and 99211–99215). 
Primary care physicians (PCPs) included those practicing family medicine, general practice, 
and internal medicine, and providers classified as multispecialty clinic or group. Oncologists 
included hematologists/oncologists, medical oncologists, surgical oncologists, radiation 
oncologists, and general surgeons. Cancer-related specialists included colorectal surgeons 
and gastroenterologists. “Other” specialists included physicians not categorized as PCPs, 
oncologists, or cancer-related specialists.
To control for comorbidity and its effect on the physicians visited and preventive medical 
services received, we calculated the Charlson comorbidity index [23]. Comorbidity was 
derived from claims occurring after the 5th anniversary date of diagnosis through the 1st day 
of the 6th anniversary date of diagnosis.
We calculated descriptive statistics for the following demographic and clinical 
characteristics of API (Chinese, Japanese, and other API) and white CRC survivors: mean 
age at the time of CRC diagnosis, sex, AJCC stage (I, II, and III/IV), comorbidity index 
(mean value and categories—0, 1, and ≥2), SEER Registry Site (Hawaii, Seattle-Puget 
Sound, Los Angeles, San Francisco-Oakland, San Jose-Monterey, Greater California, and 
other SEER registries, grouping Detroit, Iowa, New Mexico, Utah, Atlanta, Rural Georgia, 
Kentucky, Louisiana, and New Jersey together), number of previous cancer diagnoses (0, 1, 
or more than 1), year of diagnosis, and the resident census tract poverty level based on the 
percentage of census tract residents living below the federal poverty level in 2000, which is 
expressed as quartiles based on the distribution among the total study population (0–3.90, 
3.91–6.76, 6.77–11.67, and ≥11.68 %). As a number of survivors from API ethnic groups 
other than Chinese and Japanese were small, their data were combined and categorized as 
“other API.” Similarly, the numbers of API survivors with stages III and IV CRC were 
small; therefore, we collapsed these stages into a single stage category (stage III/IV).
To compare patterns of physician specialties visited during the follow-up period, we 
calculated the proportion of API and white CRC survivors who had one or more visits with 
the following physicians: PCPs with no visit to an oncologist; visits to both PCPs and 
oncologists; visits to an oncologist but not to a PCP; visits to a cancer-related specialist; and 
no visits to a PCP, an oncologist, or a cancer-related specialist, including visits to other 
physician specialists only or no physician visits. We calculated the mean number of 
physician visits in each of these categories and visits to any physician during the follow-up 
period, all of which were adjusted by the number of follow-up years to represent average 
annual physician visits.
We assessed differences between API and white CRC survivors using chi square tests for 
categorical variables and one-way analysis of variance for age at diagnosis. As the 
comorbidity index and the number of medical visits by provider types were not normally 
distributed, we used the Kruskal–Wallis test. All values were considered statistically 
significant if P <0.05.
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We calculated individual follow-up time in years to control for its effect in multivariable 
analyses. We controlled for the total number of physician visits during the follow-up period. 
After controlling for demographic factors and selected clinical characteristics, we conducted 
multivariable logistic regression to determine whether API and white CRC survivors 
differed on receipt of preventive medical services and whether physician type influenced 
receipt of these services. We built separate models for receipt of influenza vaccine, 
pneumococcal vaccine, cholesterol screening, mammography among women aged 65–74 
years, and bone density screening among women. As mammography and bone density 
testing were limited to female survivors, we also conducted a separate analysis to assess 
differences in survivor characteristics by gender. Receipt of each preventive service (at least 
one service provided during the follow-up period) was the dependent variable, whereas 
independent variables included providers visited, API or white race, age at diagnosis, sex (in 
models that included both males and females), stage at diagnosis, comorbidities, number of 
primary cancers, SEER registry site, number of follow-up years, total number of physician 
visits during the follow-up period, and poverty level. The referent group in this model was 
“PCP only.” Because sample sizes were small for the oncologist only category and other 
physician specialties, we did not disaggregate APIs by ethnic background in the final 




The mean age at diagnosis of the 9,737 long-term CRC survivors ranged from 71.8 years 
(other API) to 74.3 years (both Chinese and white patients; Table 1). Nearly two thirds of 
API survivors resided in Hawaii and Los Angeles. Compared with white survivors, 
significantly lower percentages of API survivors were diagnosed at stage I, had no 
comorbidities, and resided in census tracts where 3.9 % or less of the population lived below 
the federal poverty level. Statistically significant differences in the survivors’ characteristics 
did not change when we restricted the demographic analysis to women.
Vaccinations
From the beginning of survivors’ 5-year anniversary date of diagnosis through the end of the 
study follow-up period, receipt of influenza vaccine was higher (P <0.0001) among API 
survivors (81.4 %) compared with white survivors (73.1 %; Table 2). Survivors who visited 
both PCPs and oncologists were more likely to receive influenza vaccine (P <0.0001) and 
pneumococcal vaccine (P <0.0001) compared with those who visited other physician 
specialists (Table 3), but these associations did not remain significant after adjusting for 
demographic and clinical characteristics. Factors that increased the odds of receiving the two 
vaccines included visiting a PCP only, living in a certain SEER registry site, and visiting a 
physician six or more times (Table 4). API race and older age at diagnosis were other 
predictors of receipt of influenza vaccine.
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Receipt of cholesterol screening was higher (P <0.0001) among API survivors (83.5 %) 
compared with white survivors (74.3 %; Table 2). Among Asian subgroups, Japanese 
American survivors were more likely to receive this test than other groups. Receipt of lipid 
testing was also significantly higher among survivors who visited both PCPs and oncologists 
compared with those who saw other physician specialties (Table 3). In our multivariable 
model, however, visits to PCPs only increased the odds of receiving this test. Other 
predictors included API race, earlier stage and younger age at diagnosis, and residing in 
census tracts with lower poverty levels (Table 4).
Mammography
Receipt of mammography was significantly higher among white survivors (69.3 %) 
compared with API survivors (52 %; Table 2). Survivors who visited both PCPs and 
oncologists were more likely than those who visited other physician specialties to receive 
mammography (P <0.0001; Table 3); however, the percentages were similar for those who 
visited both PCPs and oncologists and those who saw oncologists only. After adjustment for 
confounders, white race and visits to both a PCP and oncologist were still significant. Other 
predictors included living in Seattle-Puget Sound and visiting physicians more frequently.
Bone densitometry
API survivors were significantly more likely to receive bone density testing (37.8 %) 
compared with white survivors (29.8 %; Table 2). Receipt of bone densitometry was higher 
among survivors who were seen by both PCPs and oncologists (Table 3). These findings 
were no longer significant in our multivariable model. Predictors of receipt of this test 
included younger age and earlier stage at diagnosis, having no comorbidities, and living in 
an “other” SEER registry site (Table 4).
Physician mix and mean number of physician visits
The percentages of API survivors and white survivors who visited PCPs only were similar 
(55.1 and 53.6 %, respectively), as were the percentages of API and white survivors who 
saw both PCPs and oncologists (30.7 and 29.6 %, respectively; Table 5). API survivors 
visited PCPs only (P <0.0001) and both PCPs and oncologists (P <0.0001) more frequently 
than white survivors.
Discussion
Overall, higher percentages of API survivors received preventive services compared with 
white survivors, except for mammography. However, race did not remain a significant 
predictor of receipt of pneumococcal vaccine or bone density testing in our multivariable 
model. We found that survivors were more likely to visit PCPs only than cancer specialists, 
which is consistent with previous studies [15, 24]. Compared with survivors who visited 
oncologists only, those who visited PCPs only had significantly increased odds of receiving 
vaccines and cholesterol screening. Snyder and colleagues also reported that receipt of lipid 
testing was increased among survivors who visited PCPs only. However they, as well as 
Earle and colleagues, found that visits to both PCPs and oncologists were associated with 
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receipt of influenza vaccine and mammography [15, 17]. In our study, mammography was 
the only service which survivors who visited both PCPs and oncologists had significantly 
increased odds of receiving. Some of the differences between our adjusted findings and 
those reported in previous research may be attributable to our use of PCPs as a referent 
group.
The total number of physician visits also predicted receipt of preventive care in our study, 
although a dose–response relationship was less evident for mammography. Some studies 
have reported an association between frequency of physician visits and receipt of preventive 
services among long-term cancer survivors, but others have not [15, 16, 25, 26]. Our 
findings regarding the number of visits and receipt of mammography could be related to the 
fact that, in later follow-up years, some women were no longer age-eligible for this 
screening test. Other studies have reported that mammography rates among long-term CRC 
survivors decrease over time [15, 27, 28]. Physicians’ perspectives about breast cancer 
screening in older women vary and might influence their mammography practices [29, 30]. 
The increased odds of receiving mammograms observed among long-term survivors who 
visited both PCPs and oncologists compared with those who visited PCPs only might reflect 
differences in providers’ perspectives about their responsibilities in providing survivorship 
care. Cheung and colleagues reported significant disagreement between PCPs and 
oncologists regarding their roles in the medical management of cancer survivors [31].
Our findings confirm that PCPs perform a central role to ensure that long-term CRC 
survivors use preventive health services. However, survivors are more likely to receive 
mammography when their care is shared by PCPs and cancer specialists. Coordinating 
survivorship care among multiple providers can be a challenge. In 2006, the Institute of 
Medicine (IOM) reported that a fragmented health care system is one of several barriers that 
hamper health care providers’ delivery of comprehensive cancer survivorship care [32]. The 
IOM indicated that improved coordination of care among PCPs, cancer specialists, and other 
health care providers is crucial to building an integrated system of care, and recommended 
that survivors receive care plans to help manage potential long-term effects of their cancer 
and its treatment. The establishment of survivorship programs and the use of treatment 
summaries and care plans have increased since the IOM’s recommendations on cancer 
survivorship care were published [33–35]. Some organizations have also developed cancer 
survivorship guidelines [36–38]. However, lack of high-quality evidence remains a barrier to 
the development of standardized practice recommendations for post-treatment care [37]. 
Other barriers to coordinating follow-up care include limited survivorship care training for 
healthcare providers, and lack of reimbursement for cancer care planning [37].
Even though all survivors in this study had health insurance, and similar percentages of API 
and white survivors visited PCPs only and both PCPs and oncologists, receipt of preventive 
health services varied by race and Asian subgroup. These differences could be related to the 
total number of physician visits, which was associated with receipt of care and varied by 
race. Lack of full coverage by Medicare for some preventive health services throughout the 
entire study period (e.g., mammography) also could have been a barrier to use of these 
services. Carrasquillo et al. reported that beneficiaries without supplemental insurance were 
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less likely to receive partially covered services than those who had additional coverage or 
were enrolled in HMOs [39].
Studies examining use of preventive care services among the API population, particularly 
API cancer survivors, are scarce in the published literature. Some studies have reported that, 
in the USA, fewer elderly Asians had ever received pneumococcal vaccine compared with 
whites [40, 41]. The pneumococcal vaccination rate among API CRC survivors in our study 
was slightly higher than the rate for white survivors but lower than the rate reported in the 
2009 Racial and Ethnic Approaches to Community Health across the USA (REACH U.S.) 
Risk Factor Survey for older Asian Americans (59.7 %) [42].The rate that we observed may 
have been lower because we did not assess receipt of the vaccine before survivors were 
diagnosed with CRC. The rate of receipt of influenza vaccine among API survivors (81.4 %) 
was similar to that reported in the REACH U.S. survey for older APIs (79.5 %) but higher 
than the rate reported in a survey of elderly Asian Americans in California (71 %) [42, 43]. 
We could not find data in the published literature with which to compare our findings 
regarding lipid screening among older APIs. Breast cancer screening rates were lower for 
survivors within all API subgroups compared with white survivors. Previous studies of 
mammography rates among women aged 65 years or older have reported a disparity 
between API and white females [43, 44]. Many API women report the same barriers to 
breast cancer screening as other women, but those who hold more Eastern cultural views or 
believe that screening is unnecessary if they feel okay are less likely to receive 
mammography [45, 46]. Additional studies are needed to further describe the use of 
healthcare services among APIs, particularly among API cancer survivors. Examining 
barriers to health care, including access to a medical home, health literacy, English language 
proficiency, acculturation, and immigration status, would help illuminate and define health 
disparities experienced by this population. Efforts are also needed to refine data collection 
for API and other racial and ethnic populations to allow for subgroup analyses.
Our study has limitations. First, even though we used a population-based database that 
included Asian ethnicity data, the total number of API cases was small. This limited our 
ability to conduct subgroup analyses. Second, most API cases came from Hawaii and 
selected areas in California. We controlled for SEER registry areas in our multivariable 
logistic regression analyses. However, there may have been residual confounding with 
geographic areas and provider practices in these SEER locations. Third, we were not able to 
include Medicare beneficiaries enrolled in managed care plans because they do not submit 
claims to Medicare. By 2001, Medicare HMO penetration in California was 40 % [47]. 
Fourth, grouping physician specialties into four physician categories may have masked 
differences within the categories for the type of care they provide. Studies have reported that 
the quality of physician specialty data in Medicare claims varies [48] and that claims are less 
likely to identify cancer specialists than other sources [49]. We used medical specialty 
information provided in claims data only; therefore, the information was not verified against 
provider databases. Lastly, we used Census tract-level SES as a proxy for individual-level 
SES, which may not adequately represent individual status. We also chose not to include 
place of birth in our model. This information was missing for many API (33 %) and white 
survivors (62 %), and it was a confounder for Asian ethnicity.
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Our study findings underscore the need for improved collaboration between PCPs and 
oncology specialists to clarify roles and responsibilities in cancer survivors’ long-term 
follow-up care. Cancer prevention and control entities are developing and implementing 
strategies that may improve communication between primary care providers and 
oncologists, including expansion of cancer survivorship training for healthcare practitioners, 
development of guidelines for long-term follow-up care, and support for research related to 
the development and evaluation of evidence-based survivorship care models [50, 51]. These 
efforts need to continue.
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